Becton, Dickinson and Company (BDX) Revenue CAGR:2.39%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, Becton, Dickinson and Company's Revenue CAGR averages 4.34% over 3 years and 2.52% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how Becton, Dickinson and Company's top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
BDX Revenue CAGR Chart
Becton, Dickinson and Company (BDX)
BDX Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
BDX Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $20.18B | $21.84B | +$1.66B | +8.23% | +8.23% |
| 2024 | $19.37B | $20.18B | +$806.00M | +4.16% | +4.16% |
| 2023 | $18.87B | $19.37B | +$502.00M | +2.66% | +2.66% |
| 2022 | $19.13B | $18.87B | $-261.00M | -1.36% | -1.36% |
| 2021 | $16.07B | $19.13B | +$3.06B | +19.02% | +19.02% |
| 2020 | $17.29B | $16.07B | $-1.22B | -7.03% | -7.03% |
| 2019 | $15.98B | $17.29B | +$1.31B | +8.18% | +8.18% |
| 2018 | $12.09B | $15.98B | +$3.89B | +32.17% | +32.17% |
| 2017 | $12.48B | $12.09B | $-390.00M | -3.12% | -3.12% |
| 2016 | $10.28B | $12.48B | +$2.20B | +21.41% | +21.41% |
| 2015 | $8.45B | $10.28B | +$1.84B | +21.74% | +21.74% |
| 2014 | $8.05B | $8.45B | +$392.00M | +4.87% | +4.87% |
| 2013 | $7.71B | $8.05B | +$346.00M | +4.49% | +4.49% |
| 2012 | $7.58B | $7.71B | +$124.00M | +1.64% | +1.64% |
| 2011 | $7.12B | $7.58B | +$459.62M | +6.45% | +6.45% |
| 2010 | $6.99B | $7.12B | +$137.66M | +1.97% | +1.97% |
| 2009 | $7.07B | $6.99B | $-88.22M | -1.25% | -1.25% |
| 2008 | $6.36B | $7.07B | +$715.23M | +11.25% | +11.25% |
| 2007 | $5.74B | $6.36B | +$621.69M | +10.83% | +10.83% |
| 2006 | $5.41B | $5.74B | +$323.34M | +5.97% | +5.97% |
| 2005 | $4.93B | $5.41B | +$479.94M | +9.73% | +9.73% |
| 2004 | $4.46B | $4.93B | +$471.24M | +10.56% | +10.56% |
| 2003 | $3.96B | $4.46B | +$503.15M | +12.70% | +12.70% |
| 2002 | $3.75B | $3.96B | +$206.06M | +5.49% | +5.49% |
| 2001 | $3.62B | $3.75B | +$135.97M | +3.76% | +3.76% |
| 2000 | $3.42B | $3.62B | +$199.93M | +5.85% | +5.85% |
| 1999 | $3.12B | $3.42B | +$301.50M | +9.67% | +9.67% |
| 1998 | $2.81B | $3.12B | +$306.40M | +10.90% | +10.90% |
| 1997 | $2.77B | $2.81B | +$40.70M | +1.47% | +1.47% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | $4.71B | -10.2% | -10.6% |
| Q1 2025 | $5.25B | -10.8% | +1.6% |
| Q4 2025 | $5.89B | +6.9% | +8.3% |
| Q3 2025 | $5.51B | +4.5% | +10.4% |
| Q2 2025 | $5.27B | +2.0% | +4.5% |
| Q1 2024 | $5.17B | -4.9% | +9.8% |
| Q4 2024 | $5.44B | +9.0% | +6.9% |
| Q3 2024 | $4.99B | -1.1% | +2.3% |
| Q2 2024 | $5.04B | +7.2% | +4.6% |
| Q1 2023 | $4.71B | -7.5% | +2.6% |
| Q4 2023 | $5.09B | +4.3% | +6.8% |
| Q3 2023 | $4.88B | +1.2% | +5.1% |
| Q2 2023 | $4.82B | +5.1% | +1.5% |
| Q1 2022 | $4.59B | -3.7% | -2.8% |
| Q4 2022 | $4.76B | +2.6% | -7.3% |
| Q3 2022 | $4.64B | -2.3% | +0.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Becton, Dickinson and Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Thomas E. Polen Jr.